Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study

NCT07440537 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Cutaneous Lupus Erythematosus (CLE)

Interventions

DRUG: ICP-488 Tablets
DRUG: ICP-488 Tablets
OTHER: ICP-488 Placebo

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.